Benzinga | Nov 2, 2020 04:04PM EST

Halozyme Therapeutics Q3 EPS $0.25 Beats $0.20 Estimate, Sales $65.30M Beat $60.91M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.20 by 25 percent. This is a 247.06 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $65.30 million which beat the analyst consensus estimate of $60.91 million by 7.21 percent. This is a 41.25 percent increase over sales of $46.23 million the same period last year.